Weight Loss Medicine Boom: Ozempic, Wegovy, Mounjaro Drive Pharma Profits

The weight-loss medicine market is booming, with PwC estimating it could hit $150 billion by 2030. Leading the charge is a duopoly of Novo Nordisk and Eli Lilly, whose GLP-1 drugs, commonly called weight loss medicines, are transforming obesity treatment. Nearly 1 in 8 people globally are living with obesity, more than double the rate in 1990 (WHO).

The market for GLP-1 drugs is growing rapidly. Valued at over $53 billion in 2024, it is expected to reach nearly $157 billion by 2030, according to Grand View Research. This sharp rise reflects a world grappling with weight issues. 

Let’s break down how GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are fueling a $150 billion weight-loss market. From how they work to who's leading the weight loss medicine pharma race, we cover the science, sales, and the growing global obesity crisis.

What are GLP-1 Drugs?

GLP-1 drugs, short for glucagon-like peptide-1 receptor agonists, are a class of medications originally developed to treat type 2 diabetes and now widely used for weight loss. These drugs mimic the natural GLP-1 hormone produced in the gut, which helps regulate blood sugar and appetite.

How do GLP-1 drugs work for weight loss? 

• Curbing Hunger: They signal to the brain's appetite control center, reducing hunger pangs and cravings.
• Slowing Digestion: They delay the emptying of the stomach, which leads to a longer-lasting feeling of fullness.
• Enhancing Satiety: By making you feel full more quickly and for an extended period, they naturally lead to reduced calorie intake, and weight loss over time.

Think of your digestive system as a busy Indian railway station. When you eat, it's like a train pulling into the main platform. The natural GLP-1 hormone is the station master who signals to the brain (the central control room) that a train has arrived and the platform is occupied. This signal is your body's way of saying, "I'm full." GLP-1 drugs act like an extra, highly efficient team of station masters. 

They send stronger and more persistent signals to the brain, making it feel as though the platform is constantly busy. This dramatically reduces your urge to board another "train" of food, helping you manage your intake effortlessly.

Popular GLP-1 drugs include Ozempic, Wegovy, Rybelsus (Novo Nordisk), Mounjaro, Zepbound and Zepbound (Eli Lilly). These medications have become central to tackling the global obesity crisis and are driving rapid growth in the weight-loss medicine market.

Novo Nordisk vs Eli Lilly: Ozempic, Wegovy vs Zepbound, Mounjaro

In the high-stakes weight loss drugs market, Denmark’s Novo Nordisk and American Eli Lilly have established themselves as the undisputed leaders. Together, they are forecast to capture a staggering 94% of the GLP-1 market by 2030, as per Pharmaceutical Technology. While the competitive landscape is dynamic, their current dominance is clear.

Based on prescription volume estimates, Eli Lilly holds a significant market share with its blockbuster drugs Mounjaro and Zepbound. Novo Nordisk, the pioneer in this space, remains a formidable competitor with its widely recognized products Ozempic and Wegovy. This two-horse race has effectively sidelined other pharmaceutical players, who are left to compete for the small remaining slice of the market.

How much Eli Lilly and Novo Nordisk earn from GLP-1 drugs

The revenues generated by these GLP-1 drugs are astronomical, fundamentally transforming the financial fortunes of both Novo Nordisk and Eli Lilly.

Source: Company Annual Reports 2024

In 2024, Ozempic sales reached approximately $17.46 billion, while Wegovy brought in about $8.44 billion. Eli Lilly has also seen explosive growth, driven by the remarkable performance of Mounjaro and Zepbound. In the fourth quarter of 2024 alone, Mounjaro and Zepbound generated approximately $3.5 billion and $1.9 billion in revenue, respectively. The company anticipates its 2025 revenue to be between $58.0 billion and $61.0 billion, largely driven by these drugs.

What’s Fueling The Demand For Weight Loss Drugs?

The relentless demand for GLP-1 drugs is a direct consequence of the escalating global obesity epidemic. The statistics paint a grim picture of a public health crisis spiraling out of control:

• A Worsening Epidemic: Worldwide adult obesity has more than doubled since 1990 (WHO). In 2022, 2.5 billion adults were overweight, and 890 million of them were obese.
• Staggering Economic Cost: The global economic impact of overweight and obesity is projected to surpass $4.32 trillion annually by 2035, a figure comparable to the financial impact of the COVID-19 pandemic in 2020.
• Alarming Future Projections: The crisis is set to worsen dramatically. By 2035, more than 50% of the global population (over 4 billion people) will be living with either overweight or obesity. Looking even further ahead, some studies project that by 2050, nearly 60% of the global adult population could be living with obesity.
• Deadly Consequences: Overweight and obesity are responsible for 1.6 million premature deaths annually from non-communicable diseases like heart disease, diabetes, and cancer.
• Systemic Failure: Most countries are woefully unprepared to handle the crisis. Only 7% of national health systems are considered adequately prepared to tackle obesity, and two-thirds of countries lack key policies to address it.
  Source: World Health Organization, World Obesity Federation, World Obesity Atlas

These numbers show just how serious the global obesity crisis has become, creating a strong demand for effective weight-loss treatments. As this health issue continues to grow, Novo Nordisk and Eli Lilly have emerged as the key players, offering medications that millions are now relying on. With both medical need and market demand rising, their role and their impact is only expected to become bigger.

Disclaimer:

The content is meant for education and general information purposes only. Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Past performance is not indicative of future returns. The securities are quoted as an example and not as a recommendation. This in no way is to be construed as financial advice or a recommendation to invest in any specific stock or financial instrument. The Company strongly encourages its users/viewers to conduct their own research, and consult with a registered financial advisor before making any investment decisions. All disputes in relation to the content would not have access to an exchange investor redressal forum or arbitration mechanism. Registered office address: Office No. 507, 5th Floor, Pragya II, Block 15-C1, Zone-1, Road No. 11, Processing Area, GIFT SEZ, GIFT City, Gandhinagar – 382355. IFSCA Broker-Dealer Registration No. IFSC/BD/2023-24/0016, IFSCA DP Reg No: IFSC/DP/2023-24/010.